Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2515254 | 0.98 | GPR35 (0.41) | GPR35NSD2GAAPLCG1DNMT1 | |
| Hydrochloric Acid SCHEMBL27566213 | 0.98 | GPR35 (0.41) | GPR35NSD2GAAPLCG1DNMT1 | |
| SCHEMBL27633926 | 0.85 | LMNA (0.44) | GAAVCAM1ALDH1A1TSHR | |
| Benzamide SCHEMBL28753889 | 0.85 | VCAM1 (0.43) | GAAL3MBTL1CA1CA2VCAM1 | |
| SCHEMBL1938624 | 0.84 | VCAM1 (0.42) | GPR35CA1CA2MMP1MMP2 | |
| SCHEMBL27633655 | 0.83 | PARP1 (0.41) | GAAL3MBTL1CA1CA2VCAM1 | |
| Silver SCHEMBL2515251 | 0.82 | GPR35 (0.38) | GPR35CA1CA2MMP1MMP2 | |
| SCHEMBL1185703 | 0.82 | VCAM1 (0.49) | GPR35CA1CA2VCAM1ALDH1A1 | |
| SCHEMBL7769090 | 0.82 | TSHR (0.41) | GPR35CA1CA2MMP1MMP2 | |
| SCHEMBL15880676 | 0.81 | CA1 (0.53) | GPR35DNMT1CA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| CN-1678306-A | -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases | BOEHRINGER INGELHEIM PHARMA (US) | 2005-10-05 | — | — | CN | claimed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | claimed |
| CN-1665802-A | Bisarylsulfonamide compounds and their use in cancer therapy | CYCLACEL LTD (GB) | 2005-09-07 | — | — | CN | claimed |
| EP-1539141-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | claimed |
| US-20040097574-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-05-20 | — | — | US | claimed |
| WO-2004019935-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | claimed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | claimed |
| CN-101115755-B | Pyrazolo-pyrimidine derivatives as MGLUR2 antagonists | HOFFMANN LA ROCHE | 2013-01-16 | — | — | CN | disclosed |
| US-8034533-B2 | Fluorine-free heteroaromatic photoacid generators and photoresist compositions containing the same | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| WO-2009091702-A1 | FLUORINE-FREE HETERAROMATIC PHOTOACID GENERATORS AND PHOTORESIST COMPOSITIONS CONTAINING THE SAME | INTERNATIONAL BUSINESS MACHINES CORPORTION (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090181320-A1 | FLUORINE-FREE HETEROAROMATIC PHOTOACID GENERATORS AND PHOTORESIST COMPOSITIONS CONTAINING THE SAME | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-7361659-B2 | Pyrrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
| CN-1665802-A | Bisarylsulfonamide compounds and their use in cancer therapy | CYCLACEL LTD (GB) | 2005-09-07 | — | — | CN | disclosed |
| EP-1539141-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004019935-A1 | -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097574-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | GPR35 175/4885NSD2 4155/4885GAA 2735/4885 |
| US-20090181320-A1 | FLUORINE-FREE HETEROAROMATIC PHOTOACID GENERATORS AND PHOTORESIST COMPOSITIONS CONTAINING THE SAME | PFAS, PFN1, FRS2 | GPR35 718/4885NSD2 1435/4885GAA 2724/4885 |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CCNL2, TP53, MDM2 | GPR35 3233/4885NSD2 709/4885GAA 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.